Location · Raleigh, NC
Clinical trials in Raleigh, NC
476 recruiting studies have a site in the Raleigh area, and 167 of them accept healthy volunteers. The area includes Durham, Chapel Hill, Cary, Morrisville, Wake Forest, Apex and nearby cities.
476 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- Recruiting
Onyx™ Liquid Embolic IDE Clinical Study
Medtronic Endovascular
- Location
- Phoenix, AZ + 19 other US sites
- Eligibility basics
- Ages 22+
- Recruiting
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
Reprieve Cardiovascular, Inc
- Location
- Irvine, CA + 33 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Sanofi
- Location
- Scottsdale, AZ + 33 other US sites
- Eligibility basics
- Ages 1–25
- RecruitingPhase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb
- Location
- Phoenix, AZ + 90 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Insmed Incorporated
- Location
- Los Angeles, CA + 12 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
SAb Biotherapeutics, Inc.
- Location
- San Francisco, CA + 20 other US sites
- Eligibility basics
- Ages 5–40
- RecruitingPhase 1
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Merck Sharp & Dohme LLC
- Location
- Birmingham, AL + 20 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1/Phase 2
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
AskBio Inc
- Location
- Irvine, CA + 4 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sanofi
- Location
- Cullman, AL + 33 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
LEO Pharma
- Location
- Birmingham, AL + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development, LLC
- Location
- Anaheim, CA + 23 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
AstraZeneca
- Location
- Birmingham, AL + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
Epygenix
- Location
- Miami, FL + 16 other US sites
- Eligibility basics
- Ages 2–55
- RecruitingPhase 2/Phase 3
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Novartis Pharmaceuticals
- Location
- Oakland, CA + 17 other US sites
- Eligibility basics
- Ages 0 mo–100
- RecruitingPhase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Incyte Corporation
- Location
- Birmingham, AL + 73 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals
- Location
- St Louis, MO + 8 other US sites
- Eligibility basics
- Ages 2–100
- RecruitingPhase 2
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
Teva Branded Pharmaceutical Products R&D LLC
- Location
- La Jolla, CA + 9 other US sites
- Eligibility basics
- Ages 30+
- Recruiting
AtraUmatic Laparoscopic HerNia Repair Clinical Investigation to Evaluate the Safety and Performance of The ECLIPSIUM System for Mesh Fixation IDE
Tissium
- Location
- Chicago, IL + 7 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 2
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
Aspeya, Inc.
- Location
- Phoenix, AZ + 19 other US sites
- Eligibility basics
- Ages 18–65
- Recruiting
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
W.L.Gore & Associates
- Location
- Phoenix, AZ + 20 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
- Location
- Phoenix, AZ + 44 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Xenon Pharmaceuticals Inc.
- Location
- Los Angeles, CA + 14 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment
Travere Therapeutics, Inc.
- Location
- Phoenix, AZ + 11 other US sites
- Eligibility basics
- Ages 12–65